Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5,10,15,20-tetrakis(carboxyphenyl)porphine (TCPP) is a synthetic meso-substituted porphyrin compound primarily utilized as a research reagent and photosensitizer in photodynamic therapy (PDT). It is characterized by its ability to generate reactive oxygen species (ROS), such as singlet oxygen, upon activation by specific wavelengths of light, leading to localized oxidative damage and cell death. Research has particularly focused on its efficacy against *Leishmania* parasites, where its metalloporphyrin derivatives, such as the Zinc(II) complex, have demonstrated significant antiparasitic activity. Additionally, the Manganese(III) derivative of TCPP functions as a cell-permeable superoxide dismutase (SOD) mimetic and peroxynitrite scavenger, offering potential antioxidant and cytoprotective applications. While widely used in chemical and biological research, TCPP is not currently developed as a branded pharmaceutical product by a specific commercial entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5,10,15,20-tetrakis(carboxyphenyl)porphine.